1. Home
  2. |Insights
  3. |Government Considers On-Line Public Access To Contracts And Task/Delivery Orders

Government Considers On-Line Public Access To Contracts And Task/Delivery Orders

Client Alert | 1 min read | 05.13.10

On May 13, 2010, the FAR Councils published an advance notice of proposed rulemaking, FAR Case 2009-004, Enhancing Contract Transparency, seeking industry input on amending the FAR to enable public posting of "the text of contracts and task and delivery orders . . . . without violating statutory and regulatory prohibitions against disclosing protected information belonging to the Government or contractors." The ANPR observes that (i) "it may not be practical to apply FOIA procedures before posting in every case"; (ii) the "Councils are looking into methods for identifying the types of information that should not be posted or released to the public, as well as means for electronic processing and posting, and development of provision or clause requirements for successful offerors to provide a redacted copy of the contract"; and (iii) the "Councils are also requesting suggestions for how best to protect the types of information through redacting, locating all such information in a standard place in the contract, or other possible methods to be considered."

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...